Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2022 - 04 - 28 save search
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 0.68%
C: -0.26%
CNSP | News | $0.209 -0.48% 26K
|
Health Technology
|
| O: 8.65%
H: 0.0%
C: -6.34%
treatment approval berubicin potential glioblastoma
USD 438.03 Mn growth expected in Krabbe Disease Treatment Market | North America to emerge as key market | Technavio
Published: 2022-04-28 (Crawled : 16:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
GLAXF | News | $19.54 2.6K
|
Health Technology
|
| O: -3.19%
H: 1.56%
C: 1.56%
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
NVS | News | $97.515 0.24% 820K
|
Health Technology
|
| O: -0.38%
H: 0.0%
C: 0.0%
GSK | News | $40.73 -1.24% 360K
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
ABBV | News | $168.1 -0.85% 670K
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
america treatment disease growth market
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
Published: 2022-04-28 (Crawled : 13:00) - biospace.com/
ZYME | $8.57 0.12% 34K
|
Health Technology
|
| O: 0.0%
H: 1.84%
C: 1.43%
treatment cancer enroll her2- her2
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
NILE 4 | $0.1225 0.0%
|
n/a
|
| O: -2.93%
H: 3.88%
C: 0.64%
ALZN | $0.7256 5.3K
|
Professional, Scientific, and T...
|
| O: 5.59%
H: 1.6%
C: -2.25%
al001 treatment dementia trial alzheimer’s phase 1 alzheimer's
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
NILE 4 | $0.1225 0.0%
|
n/a
|
| O: -2.93%
H: 3.88%
C: 0.64%
ALZN | $0.7256 5.3K
|
Professional, Scientific, and T...
|
| O: 5.59%
H: 1.6%
C: -2.25%
al001 treatment dementia trial alzheimer’s phase 1 alzheimer's
Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
LLY | News | $731.46 -1.91% 700K
|
Health Technology
|
| O: 4.44%
H: 1.53%
C: 0.43%
tst002 treatment antibody china osteoporosis
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
Published: 2022-04-28 (Crawled : 10:00) - biospace.com/
CARA | $0.701 -0.86% 45K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -7.09%
kapruvia treatment hemodialysis
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.